Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

400%

4 of 1 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03643562Phase 3Terminated

Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

Role: lead

NCT03879655Phase 2Terminated

Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1

Role: lead

NCT04958642Phase 2Terminated

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

Role: lead

NCT02534844Phase 2Completed

VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

Role: lead

All 4 trials loaded